Response of Patients on Surveillance for Prostate Cancer to Dutasteride

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

Hypothesis: That, in men on surveillance for favorable risk prostate cancer treated with dutasteride, prostate specific antigen (PSA) kinetics is of value in identifying those men who harbor occult high grade prostate cancer.

The study will determine the prevalence of a secondary rise in PSA > 0.5 ng/ml and the PSA doubling time in subjects on surveillance being treated with dutasteride.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunnybrook Health Sciences Centre
• Collaborator: Toronto Sunnybrook Regional Cancer Centre
• Treatments: Dutasteride

Criteria

Inclusion Criteria:

• Patients on active surveillance for favorable risk prostate cancer who have been treated with dutasteride following the diagnosis of cancer.